Carcinoma of Unknown Primary | Hematology-Oncology Therapy, 2e | AccessHemOnc

INTRODUCTION

Epidemiology

Favorite Table | Download (.pdf) | Print

Epidemiology

Incidence:	Unknown^✫ (Estimated at 30,000–45,000 patients/year)	Stage at Presentation
Median age:	Varies by histology (usually sixth decade)	Local/regional:	<10%
Male to female ratio:	M ≅ F	≥2 sites:	>90%
^✫Due to patient heterogeneity and tumor registry misclassification Cancer Facts and Figures 2013, the America Cancer Society Greco FA, Hainsworth JD. In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 8th ed. Lippincott; 2008:2363–2388 Hainsworth JD et al. J Clin Oncol 1991;9:1931–1938 Hainsworth JD, Greco FA. N Engl J Med 1993;329:257–263

Pathology

Favorite Table | Download (.pdf) | Print

Pathology

Adenocarcinoma (well differentiated or moderately differentiated)	60%
Poorly differentiated carcinoma/(± features of adenocarcinoma)	29%
Poorly differentiated malignant neoplasm	5%
Squamous carcinoma	5%
Neuroendocrine carcinoma	1%
Greco FA, Hainsworth JD. In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 8th ed. Lippincott; 2008:2363–2388 Hainsworth JD, Greco FA. N Engl J Med 1993;329: 257–263

Work-up

Clinical evaluation

Where appropriate:

Positron emission tomography (PET)
Prostate specific antigen (PSA)
Mammography, bronchoscopy, and panendoscopy (particularly for squamous carcinomas)

Pathologic studies

Core needle or excisional biopsy preferred over fine-needle aspiration (FNA)/cytology (consider rebiopsy if insufficient material from initial biospy)
Immunohistochemistry (IHC) analyses for:
- PSA in men
- Estrogen receptor (ER) in women
- Progesterone receptor (PR) in women
- HER2/neu overexpression in women
- CD 117
- Consider gene signature profiling of tissue of origin

Where appropriate:

Focused Work-up

Favorite Table | Download (.pdf) | Print

Focused Work-up

Presentation	Men	Women
Head and neck or supraclavicular adenopathy	ENT exam Chest/abdominal CT PSA, testicular ultrasound	ENT exam Chest/abdominal CT Mammography, ER/PR Pathologic evaluation
Axillary adenopathy	Chest/abdominal CT PSA	Chest/abdominal CT Mammography, ER/PR (Consider ultrasound or MRI)
Mediastinal involvement	Chest/abdominal CT HCG/AFP PSA	Chest/abdominal CT HCG/AFP Mammography, ER/PR
Chest (effusion and/or nodules) involvement	Chest/abdominal CT PSA	Chest/abdominal/pelvic CT Mammography, ER/PR CA 125
Peritoneal involvement	Chest/abdominal/pelvic CT PSA	Chest/abdominal/pelvic CT Mammography, ER/PR CA 125
Retroperitoneal mass	Chest/abdominal/pelvic CT PSA HCG/AFP Testicular ultrasound	Chest/abdominal/pelvic CT Mammography, ER/PR CA 125
Inguinal adenopathy	Abdominal/pelvic CT PSA	Abdominal/pelvic CT Mammography, ER/PR CA 125
Hepatic involvement	Chest/abdominal/pelvic CT Colonoscopy AFP PSA	Chest/abdominal/pelvic CT Colonoscopy AFP Mammography, ER/PR
Skeletal involvement	Bone scan PSA	Bone scan Mammography, ER/PR
Brain involvement	Chest/abdominal CT	Chest/abdominal CT Mammography, ER/PR
Greco FA, Hainsworth JD. In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 8th ed. Lippincott; 2008:2363–2388

Survival

Survival varies by histology and clinical subsets

...

GET ACCESS TO THIS RESOURCE

Username

Password

Forgot Username? Forgot Password?

Get Free Access Through Your Institution

Contact your institution's library to ask if they subscribe to McGraw-Hill Medical Products.

What is MyAccess?